Dr. Joseph Schappert MD
Medical Director , PROVIDENCE HEALTH CARE
Member of the Healthcare Council
Council Member Biography
Joseph Schappert, MD, is the Chief Medical Officer at Pathology Associates Medical Laboratories (PAML) and the Medical Director for Providence Health Care System. He was previously the Global Medical Director at ICON Central Laboratories, where he was involved in innovative and state-of-art information technology, flow cytometric and molecular diagnostic solutions in support of clinical trials conducted worldwide. Dr. Schappert has also served as the Vice Chair of Pathology and Laboratory Medicine at the Beth Israel Medical Center and St. Luke's Roosevelt Hospital Center. He has expertise in infectious disease testing, cardiac markers, coagulation testing, point of care testing, laboratory automation, and molecular diagnostics. Dr. Schappert has presented on these subjects at local, national, and international conferences. He has also worked extensively with major diagnostic companies. (This is me - Update Profile)
Employment History
- 2009 - Unspecified
- Chief Medical Officer , PATHOLOGY ASSOCIATES MEDICAL LABS (PAML)
- 2009 - Unspecified
- Medical Director , PROVIDENCE HEALTH CARE
- 2007 - 2009
- Medical Director , ICON CENTRAL LABORATORIES, INC.
- 2002 - 2007
- Vice Chair of Pathology and Laboratory Medicine, BETH ISRAEL MEDICAL CENTER (INC)
- 1998 - 2007
- Vice Chair of Pathology and Laboratory Medicine, ST LUKE'S-ROOSEVELT HOSPITAL CENTER
GLG NewsSM Analyses by Joseph Schappert(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
February 13, 2009
Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics | www.tmcnet.com
The ability of pharma and biotech to leverage the rapid expansion in our knowledge base on cell surface, nuclear and cytoplasmic signaling and messaging systems has and will continue to produce novel targeted molecules. To identify which patients will respond and potential surrogate markers for the assessment of a molecule's success will require reagents that are applied to histologic sections. These capabilities, combined with imaging and data reduction of the stained sections, should be anticipated to provide a very lucrative market for companies in this diagnostic arena and to facilitate the timely introduction of effective novel markers.
-
Novel molecules and diagnostic tests
February 19, 2008
Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Diagnostic tools are availible to identify these adverse effects at an early stage in their clinical development. These tools should mitigate the seriousness of these adverse events.
-
Microrganisms elude our control
March 5, 2007
Proof Nailed Down that Antibiotics Use Leads to Resistance | www.medpagetoday.com
Our experience with antibiotics has consistently shown that resistance occurs within 3-5 years of their widespread utilization. Our more recent experience with antiviral agents has been similar. Without diminishing the important role that antimicrobials have played in our recent history, it has also underscored their limitations. While this is of concern, there is also considerable concern in the international microbiology community regarding mutations within microorganisms that would allow them to 'jump species' and infect humans, or would enhance the virulence of existing pathogens. This fear is enhanced by the indiscriminate utilization of antimicrobial agents associated with ‘modern’ agricultural practices worldwide, which are changing the microbial ecology and potentially selecting out new pathogens to humans and/or to our food supply.
-
The future of clinical laboratory diagnostics
March 5, 2007
GE to acquire Abbott's invitro and point of care diagnostics businesses | egems.gehealthcare.com
The purchase of Abbott Diagnostics (ADD) by General Electric follows the purchase of Bayer Diagnostics and DPC by Siemens. It can be anticipated that GE will purchase a second diagnostics company. Since this is part of a restructuring of the diagnostics industry away from pharmaceutical companies to electronics companies, it should also be anticipated that Philips and possibly IBM would enter this arena in the very near future
Leading institutions connect with Joseph Schappert through GLG
GLG Study Groups with Joseph Schappert(?)
| Study Group Name | No. Members |
|---|---|
| Pathologists (US) | 792 |
| Generic Drug Economic Experts | 766 |
| Economic Experts on Managed Care | 714 |
| Users of BRACAnalysis Testing for Breast and Ovarian Cancer (US) | 95 |
| Users of Mass Spectrometers in the U.S. | 92 |
GLG Live Meetings with Joseph Schappert(?)
Joseph Schappert has not participated in any GLG Live Meetings.